PLRX PLIANT THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1746473 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY48.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.3%
ROA-40.5%
ROIC (approx.)-63.7%
Asset turnover—
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.00x
Current ratio8.05x
Interest coverage-698.18x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $1.58M | $9.69M | $7.57M |
| R&D expense | $109.16M | $169.31M | $127.80M | $96.94M | $77.55M |
| SG&A expense | $47.22M | $59.05M | $57.93M | $39.95M | $27.56M |
| Operating income | -$156.37M | -$228.37M | -$184.15M | -$127.20M | -$97.53M |
| Interest expense | $2.56M | $3.02M | $1.27M | $791,000 | $0 |
| Pretax income | -$149.30M | -$210.30M | -$161.30M | -$123.30M | -$97.30M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$149.34M | -$210.30M | -$161.34M | -$123.32M | -$97.26M |
| EBITDA | -$154.68M | -$226.24M | -$182.30M | -$125.38M | -$96.00M |
| EPS (basic) | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 |
| EPS (diluted) | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 61.37M | 60.54M | 58.72M | 42.02M | 35.85M |
| Balance sheet | |||||
| Cash & equivalents | $45.45M | $72.67M | $64.72M | $33.68M | $51.66M |
| Short-term investments | $145.50M | $284.54M | $431.01M | $297.50M | $148.93M |
| Receivables | — | — | $0 | $1.98M | $2.00M |
| Current assets | $196.45M | $362.26M | $505.50M | $340.31M | $209.44M |
| PP&E, net | $2.94M | $5.53M | $3.57M | $4.49M | $4.61M |
| Total assets | $225.23M | $396.95M | $512.15M | $350.61M | $221.22M |
| Current liabilities | $16.36M | $33.22M | $28.52M | $23.91M | $16.83M |
| Long-term debt | $0 | $30.21M | $10.05M | $9.93M | $0 |
| Total debt | $0 | $30.21M | $10.05M | $9.93M | $0 |
| Total liabilities | $44.02M | $92.87M | $38.58M | $37.27M | $22.16M |
| Shareholders' equity | $181.21M | $304.08M | $473.58M | $313.34M | $199.06M |
| Net debt | -$45.45M | -$42.46M | -$54.66M | -$23.75M | -$51.66M |
| Shares outstanding | 61.45M | 60.86M | 59.92M | 48.94M | 36.08M |
| Cash flow statement | |||||
| Operating cash flow | -$128.34M | -$155.50M | -$116.36M | -$94.63M | -$75.44M |
| Capital expenditure | $374,000 | $3.85M | $921,000 | $1.76M | $1.95M |
| Free cash flow | -$128.71M | -$159.35M | -$117.28M | -$96.39M | -$77.40M |
| Investing cash flow | $134.29M | $140.34M | -$127.01M | -$150.20M | $73.70M |
| Financing cash flow | -$31.70M | $23.12M | $274.40M | $226.85M | $2.53M |
| Depreciation & amortization | $1.70M | $2.12M | $1.84M | $1.82M | $1.53M |
| Stock-based compensation | $26.23M | $37.63M | $44.48M | $22.60M | $10.44M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.